A Phase 2 interventional study of Baricitinib and Placebo in Diabetic Kidney Disease, sponsored by Eli Lilly and Company. Completed at 45 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-30.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.
Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 41st largest by enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2012, is one of 54 in phase 2, and was the 60th registered.
543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–80
Medical University of South Carolina · Sites in United States
Ages 18–75
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in United States
Ages 18–75 · Healthy volunteers
Seattle Children's Hospital · Sites in United States
Ages 14–40
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
153 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 61 · Phase 3 16 · Phase 4 10
First in 1981; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 78 across 388 interventional studies indexed under Diabetic Nephropathies.
Median enrollment 79 across the 120 interventional studies, 175 across the 31 observational. Of the 115 that completed or were terminated, 46 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
70 of 153 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 3 studies filed under Diabetic Nephropathies — fewer than ten, so there is no comparison to draw.
12 of the studies in Diabetic Nephropathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05759468Brigham and Women's HospitalNAD Augmentation in Diabetes Kidney Disease | 2026-11-30 |
| NCT07022418Medical University of South CarolinaFormoterol in Diabetes | 2026-12 |
| NCT04802395Renalytix AI, Inc.Real World Evidence Clinical Utility Study of KidneyIntelX | 2026-12-01 |
| NCT05507892University of Colorado, DenverRenal Mechanism of SGLT2 Inhibition | 2026-12-15 |
| NCT07024823AstraZenecaA Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants | 2027-01-29 |
Add all 12 to your calendar (.ics) → With an account.
Among the 153 studies in Diabetic Nephropathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a dose ranging study to evaluate the safety and efficacy of baricitinib in the treatment of participants with mild to moderate diabetic kidney disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered orally, given as three placebo tablets in the morning and one placebo tablet in the evening for 24 weeks.
Drug: Placebo
Administered orally, 0.75 mg given as one 0.75 mg tablets and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
Drug: Baricitinib · Drug: Placebo
Administered orally, 0.75 mg given as one 0.75 tablet and 2 placebo in the morning and one 0.75 mg tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one 0.5 mg tablet in the evening. Placebo tablets given to maintain blind.
Drug: Baricitinib · Drug: Placebo
Administered orally, 1.5 mg given as two 0.75 mg tablets and 1 placebo tablet in the morning and one placebo tablet in the evening for 24 weeks or 1 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
Drug: Baricitinib · Drug: Placebo
Administered orally, 4 mg given as one tablet and 2 placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 2.75 mg given as two 1 mg tablets and one 0.75 mg tablet in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
Drug: Baricitinib · Drug: Placebo
Administered orally
Also known as: LY3009104, INCB28050
Administered orally
Change From Baseline in Urinary Albumin/Creatinine Ratio (UACR) at Week 24
UACR is a potential marker of chronic kidney disease, calculated as a ratio of Urinary Albumin and Urinary Creatinine. The least squares mean (LS mean) are from mixed model repeated measures (MMRM) analyses which include treatment, baseline estimated Glomerular Filtration Rate (eGFR) group (higher: 50 to 70 mL/min/1.73m² and lower: 25 to \<50 mL/min/1.73m²), visit, treatment-by-visit interaction, baseline UACR, and baseline UACR-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Urinary Monocyte Chemotactic Protein 1 (MCP-1)/Creatinine Ratio
Time frame: Baseline, Week 24
Change From Baseline in Creatinine Clearance at Week 24
Creatinine clearance is the amount of creatinine cleared from kidney within 24 hours. The LS mean was from MMRM analyses which included treatment, baseline eGRF group, visit, treatment-by-visit interaction, baseline Creatinine Clearance, and baseline Creatinine Clearance-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) at Week 24
EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state. The second part is assessed using a visual analog scale (VAS) that ranged from 0 to 100mm, where 0 is the worst health you can imagine and 100 is the best health you can imagine. The LS means are analyzed using an analysis of covariance (ANCOVA) model with treatment, baseline eGFR group, and baseline VAS score or baseline health state index score as covariates.
Time frame: Baseline, Week 24
Pharmacokinetics (PK): Area Under the Concentration-Time Curve at Steady State (AUC,ss)
Evaluable pharmacokinetic concentrations from the 2-week, 4-week, 8-week, 12-week, 16-week, 20-week and 24-week time points were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.
Time frame: Weeks 2 and 4 (1-2 hours postdose), 8 (3-6 hours postdose), 12 (in fasted state), 16 and 20 (6-9 hours postdose), 24 (in fasted state)
The study included a 24-week treatment period and a 4- to 8-week washout period where study drug was discontinued. Time to loss-of-treatment benefit (defined as a failure to maintain a 30% decrease in UACR from baseline) was evaluated at Week 28. Participants who maintained treatment benefit were followed for an additional 4 weeks.
| Milestone | Placebo | Baricitinib 0.75 mg/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg | Baricitinib 4 mg/2.75 mg |
|---|---|---|---|---|---|
| Started | 27 | 25 | 27 | 26 | 25 |
| Received at least one dose of study drug | 27 | 25 | 26 | 26 | 25 |
| Completed | 27 | 21 | 26 | 24 | 23 |
| Not completed | 0 | 4 | 1 | 2 | 2 |
| Withdrew: Inappropriately enrolled | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 3 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 1 |
| Milestone | Placebo | Baricitinib 0.75 mg/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg | Baricitinib 4 mg/2.75 mg |
|---|---|---|---|---|---|
| Started | 27 | 21 | 26 | 24 | 23 |
| Completed | 24 | 17 | 25 | 22 | 20 |
| Not completed | 3 | 4 | 1 | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 4 | 0 | 1 | 2 |
| Milestone | Placebo | Baricitinib 0.75 mg/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg | Baricitinib 4 mg/2.75 mg |
|---|---|---|---|---|---|
| Started | 6 | 6 | 8 | 6 | 12 |
| Completed | 6 | 6 | 7 | 6 | 9 |
| Not completed | 0 | 0 | 1 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 |
UACR is a potential marker of chronic kidney disease, calculated as a ratio of Urinary Albumin and Urinary Creatinine. The least squares mean (LS mean) are from mixed model repeated measures (MMRM) analyses which include treatment, baseline estimated Glomerular Filtration Rate (eGFR) group (higher: 50 to 70 mL/min/1.73m² and lower: 25 to \<50 mL/min/1.73m²), visit, treatment-by-visit interaction, baseline UACR, and baseline UACR-by-visit interaction.
| milligram/gram (mg/g) | Placebo | Baricitinib 0.75 mg/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg | Baricitinib 4 mg/2.75 mg |
|---|---|---|---|---|---|
| Change From Baseline in Urinary Albumin/Creatinine Ratio (UACR) at Week 24 | 1.12 ± 0.172 | 0.87 ± 0.155 | 0.85 ± 0.131 | 0.91 ± 0.143 | 0.66 ± 0.111 |
No measurements were reported for this outcome.
Creatinine clearance is the amount of creatinine cleared from kidney within 24 hours. The LS mean was from MMRM analyses which included treatment, baseline eGRF group, visit, treatment-by-visit interaction, baseline Creatinine Clearance, and baseline Creatinine Clearance-by-visit interaction.
| milliliter/minute (mL/min) | Placebo | Baricitinib 0.75 mg/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg | Baricitinib 4 mg/2.75 mg |
|---|---|---|---|---|---|
| Change From Baseline in Creatinine Clearance at Week 24 | 0.93 ± 0.070 | 1.09 ± 0.104 | 0.86 ± 0.069 | 0.86 ± 0.069 | 0.080 ± 0.066 |
EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state. The second part is assessed using a visual analog scale (VAS) that ranged from 0 to 100mm, where 0 is the worst health you can imagine and 100 is the best health you can imagine. The LS means are analyzed using an analysis of covariance (ANCOVA) model with treatment, baseline eGFR group, and baseline VAS score or baseline health state index score as covariates.
| Units on a Scale | Placebo | Baricitinib 0.75 mg/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg | Baricitinib 4 mg/2.75 mg |
|---|---|---|---|---|---|
| Index Score (UK Algorithm) Week 24 | 0.00 ± 0.03 | -0.03 ± 0.03 | -0.01 ± 0.03 | -0.04 ± 0.03 | 0.00 ± 0.03 |
| Index Score (US Algorithm) Week 24 | 0.00 ± 0.02 | -0.03 ± 0.02 | 0.00 ± 0.02 | -0.03 ± 0.02 | 0.00 ± 0.02 |
| Self-Perceived Health Score | 2.62 ± 2.94 | -1.97 ± 3.02 | 0.28 ± 2.95 | -5.66 ± 2.96 | 0.37 ± 3.02 |
Evaluable pharmacokinetic concentrations from the 2-week, 4-week, 8-week, 12-week, 16-week, 20-week and 24-week time points were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.
| nanomole*hour (nM*hr) | Baricitinib 0.75 mg/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg | Baricitinib 4 mg/2.75 mg |
|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration-Time Curve at Steady State (AUC,ss) | 198 ± 89.9 | 286 ± 92.4 | 388 ± 151 | 1250 ± 577 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/27 (7.4%) | 18/27 (66.7%) |
| Baricitinib 0.75 mg/0.5 mg QD | — | 0/25 (0%) | 18/25 (72%) |
| Baricitinib 0.75 mg/0.5 mg BID | — | 2/26 (7.7%) | 17/26 (65.4%) |
| Baricitinib 1.5 mg/1 mg | — | 2/26 (7.7%) | 19/26 (73.1%) |
| Baricitinib 4 mg/2.75 mg | — | 6/25 (24%) | 23/25 (92%) |
| Placebo - Washout 1 | — | 0/27 (0%) | 5/27 (18.5%) |
| Baricitinib 0.75 mg/0.5 mg QD - Washout 1 | — | 0/21 (0%) | 4/21 (19%) |
| Baricitinib 0.75 mg/0.5 mg BID - Washout 1 | — | 0/26 (0%) | 4/26 (15.4%) |
| Baricitinib 1.5 mg/1 mg - Washout 1 | — | 0/24 (0%) | 7/24 (29.2%) |
| Baricitinib 4 mg/2.75 mg - Washout 1 | — | 0/23 (0%) | 8/23 (34.8%) |
| Placebo Washout 2 | — | 0/6 (0%) | 1/6 (16.7%) |
| Baricitinib 0.75 mg/0.5 mg QD - Washout 2 | — | 0/6 (0%) | 2/6 (33.3%) |
| Baricitinib 0.75 mg/0.5 mg BID - Washout 2 | — | 1/8 (12.5%) | 1/8 (12.5%) |
| Baricitinib 1.5 mg/1 mg - Washout 2 | — | 0/6 (0%) | 0/6 (0%) |
| Baricitinib 4 mg/2.75 mg - Washout 2 | — | 0/12 (0%) | 3/12 (25%) |
| Event | Placebo | Baricitinib 0.75 mg/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg | Baricitinib 4 mg/2.75 mg | Placebo - Washout 1 | Baricitinib 0.75 mg/0.5 mg QD - Washout 1 | Baricitinib 0.75 mg/0.5 mg BID - Washout 1 | Baricitinib 1.5 mg/1 mg - Washout 1 | Baricitinib 4 mg/2.75 mg - Washout 1 | Placebo Washout 2 | Baricitinib 0.75 mg/0.5 mg QD - Washout 2 | Baricitinib 0.75 mg/0.5 mg BID - Washout 2 | Baricitinib 1.5 mg/1 mg - Washout 2 | Baricitinib 4 mg/2.75 mg - Washout 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PancreatitisGastrointestinal disorders | 1/27 | 0/25 | 0/26 | 0/26 | 0/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 1/8 | 0/6 | 0/12 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/27 | 0/25 | 0/26 | 0/26 | 2/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| AnaemiaBlood and lymphatic system disorders | 0/27 | 0/25 | 0/26 | 0/26 | 1/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| Staphylococcal infectionInfections and infestations | 0/27 | 0/25 | 0/26 | 0/26 | 1/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| DehydrationMetabolism and nutrition disorders | 0/27 | 0/25 | 0/26 | 0/26 | 1/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/27 | 0/25 | 0/26 | 0/26 | 1/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| Aortic valve incompetenceCardiac disorders | 0/27 | 0/25 | 0/26 | 1/26 | 0/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| Mitral valve incompetenceCardiac disorders | 0/27 | 0/25 | 0/26 | 1/26 | 0/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| Vitreous haemorrhageEye disorders | 0/27 | 0/25 | 1/26 | 0/26 | 0/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| Anaphylactic reactionImmune system disorders | 0/27 | 0/25 | 0/26 | 1/26 | 0/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| Event | Placebo | Baricitinib 0.75 mg/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg | Baricitinib 4 mg/2.75 mg | Placebo - Washout 1 | Baricitinib 0.75 mg/0.5 mg QD - Washout 1 | Baricitinib 0.75 mg/0.5 mg BID - Washout 1 | Baricitinib 1.5 mg/1 mg - Washout 1 | Baricitinib 4 mg/2.75 mg - Washout 1 | Placebo Washout 2 | Baricitinib 0.75 mg/0.5 mg QD - Washout 2 | Baricitinib 0.75 mg/0.5 mg BID - Washout 2 | Baricitinib 1.5 mg/1 mg - Washout 2 | Baricitinib 4 mg/2.75 mg - Washout 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/27 | 1/25 | 1/26 | 2/26 | 7/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| NasopharyngitisInfections and infestations | 1/27 | 4/25 | 4/26 | 4/26 | 3/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 1/6 | 0/8 | 0/6 | 0/12 |
| Respiratory tract infectionInfections and infestations | 0/27 | 0/25 | 0/26 | 0/26 | 0/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 1/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| GoutMetabolism and nutrition disorders | 0/27 | 1/25 | 0/26 | 0/26 | 0/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 1/6 | 0/8 | 0/6 | 0/12 |
| HypoglycaemiaMetabolism and nutrition disorders | 4/27 | 0/25 | 0/26 | 0/26 | 0/25 | 0/27 | 0/21 | 0/26 | 0/24 | 1/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| VertigoEar and labyrinth disorders | 1/27 | 0/25 | 0/26 | 0/26 | 0/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 1/8 | 0/6 | 0/12 |
| Head bangingPsychiatric disorders | 0/27 | 0/25 | 0/26 | 0/26 | 0/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 1/8 | 0/6 | 0/12 |
| NauseaGastrointestinal disorders | 0/27 | 2/25 | 0/26 | 1/26 | 3/25 | 0/27 | 0/21 | 0/26 | 1/24 | 0/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| Blood creatine phosphokinase increasedInvestigations | 2/27 | 1/25 | 1/26 | 1/26 | 3/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
| Blood creatinine increasedInvestigations | 0/27 | 2/25 | 0/26 | 0/26 | 3/25 | 0/27 | 0/21 | 0/26 | 0/24 | 0/23 | 0/6 | 0/6 | 0/8 | 0/6 | 0/12 |
All participants that received at least one dose of study drug.
| Age, Continuous(Years) | Placebo | Baricitinib 0.75/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg QD | Baricitinib 4 mg/2.75 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 64 ± 9.0 | 61 ± 10.0 | 64 ± 8.3 | 61 ± 10.4 | 63 ± 7.8 | 63 ± 9.1 |
| Sex: Female, Male(Participants) | Placebo | Baricitinib 0.75/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg QD | Baricitinib 4 mg/2.75 mg | Total |
|---|---|---|---|---|---|---|
| Female | 7 | 8 | 5 | 5 | 10 | 35 |
| Male | 20 | 17 | 21 | 21 | 15 | 94 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Baricitinib 0.75/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg QD | Baricitinib 4 mg/2.75 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 6 | 7 | 4 | 25 |
| Not Hispanic or Latino | 23 | 21 | 20 | 19 | 21 | 104 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Baricitinib 0.75/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg QD | Baricitinib 4 mg/2.75 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 2 | 2 | 1 | 9 |
| Asian | 14 | 12 | 12 | 11 | 11 | 60 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 2 | 7 | 3 | 0 | 3 | 15 |
| White | 8 | 4 | 9 | 13 | 9 | 43 |
| More than one race | 1 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | Baricitinib 0.75/0.5 mg QD | Baricitinib 0.75 mg/0.5 mg BID | Baricitinib 1.5 mg/1 mg QD | Baricitinib 4 mg/2.75 mg | Total |
|---|---|---|---|---|---|---|
| Puerto Rico | 0 | 1 | 0 | 0 | 0 | 1 |
| United States | 14 | 13 | 14 | 14 | 13 | 68 |
| Japan | 11 | 10 | 10 | 10 | 11 | 52 |
| Mexico | 2 | 1 | 2 | 2 | 1 | 8 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
The record gives a start of Aug 2012, a primary completion of Sep 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 2 years 10 months after primary completion. A results delay was requested in Jan 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib